Related references
Note: Only part of the references are listed.Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network
Helena Mosbah et al.
DIABETES OBESITY & METABOLISM (2022)
Effects of metreleptin in patients with lipodystrophy with and without baseline concomitant medication use
Kelly Adamski et al.
CURRENT MEDICAL RESEARCH AND OPINION (2021)
Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance
Vaia Lambadiari et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Familial Partial Lipodystrophy (FPLD): Recent Insights
Christos Bagias et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2020)
Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants
Hilal Sekizkardes et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Comorbidities and Survival in Patients With Lipodystrophy: An International Chart Review Study
Baris Akinci et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy
Elif A. Oral et al.
ENDOCRINE (2019)
Specific combinations of biallelic POLR3A variants cause Wiedemann-Rautenstrauch syndrome
Stefano Paolacci et al.
JOURNAL OF MEDICAL GENETICS (2018)
Clinical Utility Gene Card for: Familial partial lipodystrophy
Isabelle Jeru et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2017)
Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy
Baris Akinci et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2017)
One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes
C. Vatier et al.
DIABETES OBESITY & METABOLISM (2016)
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline
Rebecca J. Brown et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Partial and Generalized Lipodystrophy: Comparison of Baseline Characteristics and Response to Metreleptin
Talia Diker-Cohen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Divergent Metabolic Phenotype between Two Sisters with Congenital Generalized Lipodystrophy Due to Double AGPAT2 Homozygous Mutations. A Clinical, Genetic and In Silico Study
Victor A. Cortes et al.
PLOS ONE (2014)
THE CLINICAL APPROACH TO THE DETECTION OF LIPODYSTROPHY - AN AACE CONSENSUS STATEMENT
Yehuda Handelsman et al.
ENDOCRINE PRACTICE (2013)
Comparison of Efficacy and Safety of Leptin Replacement Therapy in Moderately and Severely Hypoleptinemic Patients with Familial Partial Lipodystrophy of the Dunnigan Variety
Vinaya Simha et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Progeroid Facial Features and Lipodystrophy Associated With a Novel Splice Site Mutation in the Final Intron of the FBN1 Gene
Denise Horn et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2011)
Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy
Jean Y. Park et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2007)
A LMNA splicing mutation in two sisters with severe dunnigan-type familial partial lipodystrophy type 2
Chantal F. Morel et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
A single-base mutation in the peroxisome proliferator-activated receptor γ4 promoter associated with altered in vitro expression and partial lipodystrophy
K Al-Shali et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Share Paper
